<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555776</url>
  </required_header>
  <id_info>
    <org_study_id>Gaba-tinntus-145</org_study_id>
    <nct_id>NCT00555776</nct_id>
  </id_info>
  <brief_title>Effect of Gabapentin on Idiopathic Subjective Tinnitus</brief_title>
  <official_title>Phase 2 Effect of Gabapentin on Idiopathic Subjective Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Islamic Azad University of Mashhad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Islamic Azad University of Mashhad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine wether Gabapentin which is useful for treating
      neuropathic pains, is effective on idiopathic subjective tinnitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tinnitus is the perception of sound in the absence of acoustic stimulation. It can be
      subjective or objective. .

      Despite numerous researches,no effective treatment for people who suffer from tinnitus has
      yet been stablished.

      As there are many evidences suggesting that loss of inhibition in the central nervous system
      may be responsible for many aspects of auditory dysfunction,including tinnitus; and as
      Gabapentin (Neurontin), a gama-aminobutyric acid (GABA) analogue, is an effective medication
      in conditions where inhibition in the CNS is impaired; we guess that Gabapentin might be
      useful for treating idiopathic subjective tinnitus.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Anticipated">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the sensation of Tinnitus by the patient or complete resolution of tinnitus;by the patient's scoring it from one to ten, before and after prescribing Gabapentin.</measure>
    <time_frame>two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relieve of complications of tinnitus, such as sleep difficulties.</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Subjective Tinnitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly,half of the subjects are given Gabapentin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomly,half of the subjects receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Neurontine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo is given with the same definition as Gabapentin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with subjective idiopathic tinnitus

        Exclusion Criteria:

          -  tinnitus with known underlying cause

          -  pregnant women and patients younger than 18 or older than 75 years

          -  patients with impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahboobeh Adami Dehkordi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ENT department of Mashhad azad university of mashhad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ENT department of Mashhad Azad medical university</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan razavi</state>
        <zip>91786 56553</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Bakhshaee M, Ghasemi M, Azarpazhooh M, Khadivi E, Rezaei S, Shakeri M, Tale M. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: a pilot study. Eur Arch Otorhinolaryngol. 2008 May;265(5):525-30. Epub 2007 Oct 25.</citation>
    <PMID>17960408</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>January 5, 2009</last_update_submitted>
  <last_update_submitted_qc>January 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr.Mahboobeh Adami Dehkordi</name_title>
    <organization>Assisstant professor</organization>
  </responsible_party>
  <keyword>tinnitus</keyword>
  <keyword>gabapentin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 29, 2010</submitted>
    <returned>January 20, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

